Del-desiran (AOC 1001)

Phase 3Small molecule

Del-desiran (AOC 1001) is one of 3 small molecule programs targeting Myotonic Dystrophy Type 1. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myotonic Dystrophy Type 1Enrolling by invitation

Myotonic Dystrophy Type 1Phase 3

Enrolling by invitation

Competition

Competitive Landscape

4 competitors in Myotonic Dystrophy Type 1

#DrugCompanyPhaseTrials

DYNE-101

DDyne Therapeutics

Phase 3

1 2

Del-desiran (AOC 1001)

AAvidity Biosciences, Inc.

Phase 3

1 3

PGN-EDODM1

PPepGen Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myotonic Dystrophy Type 11 trial

A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

Enrolling by invitation·AAvidity Biosciences, Inc.·Phase 3·NCT07008469·199 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Del-desiran (AOC 1001). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Del-desiran (AOC 1001) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Del-desiran (AOC 1001). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Avidity Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAvidity Biosciences, Inc.

Del-desiran (AOC 1001)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myotonic Dystrophy Type 11 trial

References

Drug Info

Quick Facts

Related News